Aurobindo Pharma received FDA approval for its generic tofacitinib citrate oral tablets on June 3, 2026, establishing a new entrant in the JAK inhibitor market. This authorization is expected to drive competition and offer significant cost savings to payers and patients compared to the branded alternative.